Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Aug 2011

Riely Gregory J, Johnson Melissa L, Medina Chanoa, Rizvi Naiyer A, Miller Vincent A, Kris Mark G, Pietanza M Catherine, Azzoli Christopher G, Krug Lee M, Pao William, Ginsberg Michelle S

Abstract excerpt

INTRODUCTION: KRAS mutations are present in 30% of lung adenocarcinomas. Salirasib prevents Ras membrane binding thereby blocking the function of all Ras isoforms. This phase II study determined the activity of salirasib in patients with advanced lung adenocarcinomas with KRAS mutations. METHODS: Two cohorts of patients with stage IIIB/IV lung adenocarcinoma were eligible: patients with tumors with KRAS mutations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to DNA, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Neoplasm Staging

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Share to Salicylates

Share to Survival Rate

Source

Identifiers

PMID: 21847063
DOI: 10.1097/JTO.0b013e318223c099

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations.PMID 21847063Read ↗

Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches.Semantic proximity Read ↗

Stratification of patients with KRAS-mutated advanced non-small cell lung cancer: improving prognostics.Semantic proximity Read ↗

Adagrasib: a novel inhibitor for KRASG12C-mutated non-small-cell lung cancer.Semantic proximity Read ↗

KRAS-targeted therapy in the treatment of non-small cell lung cancer.Semantic proximity Read ↗

KRAS Mutations in Squamous Cell Carcinomas of the LungSemantic proximity Read ↗

An evaluation of sotorasib for the treatment of patients with non-small cell lung cancer with KRASG12C mutations.Semantic proximity Read ↗

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.Semantic proximity Read ↗

KRAS mutations in non-small cell lung cancer.Semantic proximity Read ↗

Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.Semantic proximity Read ↗

Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?Semantic proximity Read ↗

Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid)Semantic proximity Read ↗

[KRAS and bronchial adenocarcinoma. Between disappointments and hopes].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.